..comes together.
In this case the plan is a paradigm shift in the way we will manage the treatment of severe asthma in years to come. The plan involves a 9-year journey taking 3 years of planning to realisation (MRC grant awarded 2014), a year of preparation and 4.5 years of clinical research.
With an investment of over £10M, the first of several key RASP-UK studies into treatment paradigms for severe asthma reports in the Lancet Respiratory Medicine journal today [1]. The findings are simultaneously being presented at the European Respiratory Society meeting.
No science is ever completed in isolation. I paraphrase Newton when I say we are all standing on the shoulders of giants. In this case our work is greatly complemented by that of GSK's CAPTAIN study [2]. In brief. the over-arching message will be that what goes up (steroid doses) doesn't necessarily come down – at least not easily. This means that we have a great combined message: "Before patients progress to high-dose corticosteroid treatment, predictive biomarkers of therapeutic response should be assessed to guide treatment decisions, because once they are established on high-dose corticosteroid treatment, corticosteroid reduction can be difficult to achieve in symptomatic patients."
References
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
Finding the best vehicle in which to publish your research findings is a perennial challenge.
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
ive years ago I was lucky enough to be involved in a project that resulted in publications
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Since 2013 we have been sharing our understanding on key issues with friends and clients via our Insider’s Insights.
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
